Future Price to Earnings: Generation Bio Corp (GBIO)
How can mass access to non-viral gene delivery be ensured? The future P/E trajectory of Generation Bio Co. (GBIO) reflects a valuation trend where the 0.00 indicator determines the parameter status. The solution lies in a transparent partnership with Moderna and the scientific expertise of the management team. Business resilience is based on the ceDNA platform, which creates a robust technological barrier for long-term commercial success.
Analytical breakdowns and data insights for company Generation Bio Corp (GBIO)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- balance sheet equity data:
- debt burden and liquidity indicators:
Total Debt to Capital Generation Bio Co.|GBIO - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Generation Bio Co.|GBIO - Company Cumulative Debt|Debt to Book Capitalization Ratio Generation Bio Co|GBIO - Company Long-Term Indebtedness|Company Current Liabilities Generation Bio|Quick Ratio generationbio.com
- earnings and market ratios statistics:
GBIO - Company Net Income|Projected Future Earnings Generation Bio Co.|GBIO - Business Payback Period|Future Price to Earnings Generation Bio Co.|GBIO - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Generation Bio Co|GBIO - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Generation Bio|GBIO - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months generationbio.com|GBIO - Earnings per share growth rate in current year|Expected earnings per share growth for next year Generation Bio Co.
Analysis of all company metrics:GBIO Generation Bio
The asset valuation of Generation Bio Co. (GBIO) requires an analysis of the cost efficiency of outsourcing DNA platforms, which minimizes operational risks and impacts future profitability. The company's current forward P/E ratio relates the market value of the share to expected net income, allowing investors to determine the extent of capital overpayment or identify potential business undervaluation based on projected cash flows.
Who Generation Bio Co. competes with
Forward P/E Multiple TEM|QGEN - Projected Price to Earnings Ratio|Future Price to Earnings Ionis Pharma IONS|Future Price to Earnings Multiple RGEN|Avidity Biosciences - Forward P/E Multiple|CRSP - Forward P/E Multiple|WGS (GeneDx) - Projected Price to Earnings|RARE: Market Cap to Future Earnings Ratio|BEAM (Beam Therapeutics Corp) - Forward P/E Multiple|Sarepta Corp (SRPT) - Market Cap to Projected Earnings|Future Price to Earnings Twist Bioscience (TWST)|TXG - Projected Price to Earnings Ratio|Future Price to Earnings Intellia Therapeutics, Inc. NTLA|STOK: Price to Future Earnings Ratio|BLFS: Projected Price to Earnings|Future Price to Earnings Multiple WVE (Wave Pharma)|MAZE: Forward P/E Multiple|SION (sionnatx.com) - Future Price to Earnings|PRME (Prime Medicine) - Forward P/E Multiple|Taysha Gene Therapies Inc (TSHA) - Market Cap to Projected Earnings|Future Price to Earnings uniQure Corp (QURE)|MGTX - Projected Price to Earnings Ratio|REGENXBIO Inc. - Projected Price to Earnings|Future Price to Earnings Multiple SLDB|Ocugen - Forward P/E Multiple|Pacific Biosciences of California, Inc. (PACB) - Projected Price to Earnings|Benitec (BNTC) - Future Price to Earnings|Projected Price to Earnings Ratio Design Corp (DSGN)|Projected Price to Earnings RCKT|4dmoleculartherapeutics.com (FDMT) - Market Cap to Projected Earnings|Forward P/E Multiple LXEO|korrobio.com (KRRO) - Forward Price to Earnings Multiple|Forward P/E Multiple EDIT (Editas)|Silence Therapeutics Corp - Future Price to Earnings|ProQR Therapeutics NV - Forward P/E Multiple|Market Cap to Projected Earnings Codexis, Inc. CDXS|Sangamo Therapeutics, Inc. (SGMO) - Future Price to Earnings|Projected Price to Earnings Ratio Nautilus Bio (NAUT)|MGX (Metagenomi, Inc) - Forward P/E Multiple|Price to Future Earnings Ratio DTIL (Precision BioSciences Inc.)|Future Price to Earnings Boundless Bio, Inc. (BOLD)|exicuretx.com - Price to Future Earnings Ratio|Forward P/E Multiple IMNN (Imunon)|Forward P/E Multiple Phio Pharmaceuticals Corp PHIO|Mustang Bio Corp - Forward P/E Multiple|Forward Price to Earnings Multiple TransCode Therapeutics (RNAZ)|BNGO: Forward P/E Multiple|Projected Price to Earnings Ratio adnas.com (APDN)|Future Price to Earnings bluebird bio|Price to Future Earnings Ratio IPA (ImmunoPrecise)|Forward P/E Multiple OMGA|OMIC - Projected Price to Earnings Ratio|Future Price to Earnings Regulus Therapeutics RGLS|Future Price to Earnings Multiple SYRS|Telesis Bio - Forward P/E Multiple|TCON - Forward P/E Multiple|UBX (Unity Bio) - Projected Price to Earnings
